Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 185 million
Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 185 million

July 08, 2020 Capital Markets and Public M&A

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 185 million in issue proceeds.

The subscription price was determined to SEK 18.50 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, William Kåge and Clara Sohlberg.

 

Related

Vinge advises parts of the consortium in connection with the public takeover offer for Cint

 The public takeover offer was announced by a consortium consisting of Triton Fund 6, Bolero, Patrick Comer and Brett Schnittlich. The offer values all shares in Cint at approximately SEK 1,989 million. The shares in Cint are listed on Nasdaq Stockholm, Mid Cap.
April 27, 2026

Nordea and SEB enters into a SEK 2,000,000,000 credit facility agreement

 On 22 April 2026, Nordea and SEB entered into a credit facility agreement in the aggregate amount of SEK 2,000,000,000 (with an accordion option for an additional SEK 400,000,000) with Humble Group AB (publ).
April 27, 2026

Vinge has advised Northmill in connection with its inaugural issuance of primary capital instruments (AT1)

 Vinge has advised Northmill Group AB in connection with its issuance of SEK 275 million primary capital instruments (so called “AT1 bonds”) with a floating rate interest of 3-month STIBOR + 690 basis points. The AT1 bonds are perpetual with a first call option after five years and are intended to be admitted to trading on Nasdaq Transfer Market and, subsequently, on Nasdaq Stockholm.
April 27, 2026